| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.7182/PRTR.11.4.6G3264UR5J551283 |
| P698 | PubMed publication ID | 11871276 |
| P2093 | author name string | Z Aalamian | |
| P2860 | cites work | Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group | Q28374428 |
| A randomised, prospective study on the conversion from cyclosporine-prednisone to cyclosporine-azathioprine at 6 months after renal transplantation | Q33503039 | ||
| Incidence and long-term cost of steroid-related side effects after renal transplantation | Q33600126 | ||
| Generic immunosuppressant use in solid organ transplantation | Q33636520 | ||
| Risk for posttransplant Diabetes mellitus with current immunosuppressive medications | Q33684389 | ||
| Immunosuppressant-induced nephropathy: pathophysiology, incidence and management | Q33804467 | ||
| Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group | Q33813285 | ||
| Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats | Q41166006 | ||
| Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression | Q41389928 | ||
| A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group | Q41439111 | ||
| Can antibody prophylaxis allow sparing of other immunosuppressives? | Q41614685 | ||
| Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation | Q42275026 | ||
| Functional and structural characteristics of experimental FK 506 nephrotoxicity | Q42557751 | ||
| Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients | Q43573422 | ||
| Rapid loss of vertebral mineral density after renal transplantation | Q44431557 | ||
| The long-term course of cyclosporine-associated chronic nephropathy | Q44825054 | ||
| Cardiac transplantation with corticosteroid-free immunosuppression: Long-term result | Q44939799 | ||
| Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine | Q46255337 | ||
| Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling | Q48230437 | ||
| Metabolic factors have a major impact on kidney allograft survival. | Q50926563 | ||
| The adverse impact of cyclosporine on serum lipids in renal transplant recipients. | Q51610594 | ||
| Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
| Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. | Q54060063 | ||
| Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients. | Q54745871 | ||
| Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression | Q57377991 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 271-82; quiz 283-4 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Progress in Transplantation: the journal for procurement and clinical transplant professionals | Q15757557 |
| P1476 | title | Reducing adverse effects of immunosuppressive agents in kidney transplant recipients | |
| P478 | volume | 11 |
| Q35626337 | A benefit-risk assessment of basiliximab in renal transplantation. |
| Q35603779 | Basiliximab: a review of its use as induction therapy in renal transplantation |
| Q36150553 | Efficacy and safety of basiliximab in kidney transplantation. |
| Q43836681 | First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation |
| Q34805437 | Rescue of calcineurin Aα(-/-) mice reveals a novel role for the α isoform in the salivary gland |
| Q42727110 | Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome |
| Q45991438 | The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. |
Search more.